Stocks
HealthEquity Financial Statements (HQY) |
||||||||||
| HealthEquitysmart-lab.ru | % | 2022 | 2023 | 2023 | 2024 | 2024 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.03.2022 | 31.01.2023 | 30.03.2023 | 31.01.2024 | 22.03.2024 | 03.09.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 756.6 | 861.7 | 861.7 | 999.6 | 999.6 | 1 112 | |||
| Operating Income, bln rub | 34.6 | 9.06 | 38.9 | 128.1 | 128.1 | 186.8 | ||||
| EBITDA, bln rub | ? | 103.0 | 171.5 | 171.5 | 281.2 | 282.4 | 350.0 | |||
| Net profit, bln rub | ? | -44.3 | -50.0 | -26.1 | 55.7 | 55.7 | 117.4 | |||
| OCF, bln rub | ? | 141.0 | 150.7 | 150.7 | 242.8 | 242.8 | 327.7 | |||
| CAPEX, bln rub | ? | 137.1 | 48.5 | 119.1 | 42.8 | 46.1 | 498.3 | |||
| FCF, bln rub | ? | 3.91 | 102.1 | 31.5 | 200.0 | 196.8 | -170.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 383.1 | 481.0 | 452.4 | 401.7 | 401.7 | 428.1 | ||||
| Cost of production, bln rub | 332.9 | 371.7 | 371.7 | 469.7 | 377.0 | 497.4 | ||||
| R&D, bln rub | 157.4 | 193.4 | 193.4 | 218.8 | 218.8 | 225.1 | ||||
| Interest expenses, bln rub | 36.6 | 48.4 | 48.4 | 55.5 | 55.5 | 54.5 | ||||
| Assets, bln rub | 3 107 | 3 089 | 3 089 | 3 164 | 3 164 | 3 514 | ||||
| Net Assets, bln rub | ? | 1 853 | 1 896 | 1 896 | 2 035 | 2 035 | 2 157 | |||
| Debt, bln rub | 1 008 | 994.5 | 994.5 | 933.1 | 933.1 | 1 157 | ||||
| Cash, bln rub | 225.4 | 254.3 | 254.3 | 404.0 | 404.0 | 326.9 | ||||
| Net debt, bln rub | 782.8 | 740.2 | 740.2 | 529.2 | 529.2 | 830.6 | ||||
| Ordinary share price, rub | 53.4 | 60.9 | 60.9 | 75.6 | 75.6 | 66.2 | ||||
| Number of ordinary shares, mln | 83.1 | 84.4 | 84.4 | 85.6 | 85.6 | 87.1 | ||||
| Market cap, bln rub | 4 443 | 5 138 | 5 138 | 6 467 | 6 467 | 5 769 | ||||
| EV, bln rub | ? | 5 225 | 5 879 | 5 879 | 6 996 | 6 996 | 6 600 | |||
| Book value, bln rub | -766 | -689 | -689 | 387 | -449 | -745 | ||||
| EPS, rub | ? | -0.53 | -0.59 | -0.31 | 0.65 | 0.65 | 1.35 | |||
| FCF/share, rub | 0.05 | 1.21 | 0.37 | 2.34 | 2.30 | -1.96 | ||||
| BV/share, rub | -9.22 | -8.16 | -8.16 | 4.52 | -5.25 | -8.55 | ||||
| EBITDA margin, % | ? | 13.6% | 19.9% | 19.9% | 28.1% | 28.3% | 31.5% | |||
| Net margin, % | ? | -5.85% | -5.81% | -3.03% | 5.57% | 5.57% | 10.6% | |||
| FCF yield, % | ? | 0.09% | 1.99% | 0.61% | 3.09% | 3.04% | -2.96% | |||
| ROE, % | ? | -2.39% | -2.64% | -1.38% | 2.74% | 2.74% | 5.44% | |||
| ROA, % | ? | -1.43% | -1.62% | -0.85% | 1.76% | 1.76% | 3.34% | |||
| P/E | ? | -100.3 | -102.7 | -196.5 | 116.1 | 116.1 | 49.2 | |||
| P/FCF | 1 135 | 50.3 | 163.0 | 32.3 | 32.9 | -33.8 | ||||
| P/S | ? | 5.87 | 5.96 | 5.96 | 6.47 | 6.47 | 5.19 | |||
| P/BV | ? | -5.80 | -7.46 | -7.46 | 16.7 | -14.4 | -7.74 | |||
| EV/EBITDA | ? | 50.7 | 34.3 | 34.3 | 24.9 | 24.8 | 18.9 | |||
| Debt/EBITDA | 7.60 | 4.32 | 4.32 | 1.88 | 1.87 | 2.37 | ||||
| R&D/CAPEX, % | 114.8% | 398.3% | 162.3% | 511.0% | 474.9% | 45.2% | ||||
| CAPEX/Revenue, % | 18.1% | 5.63% | 13.8% | 4.28% | 4.61% | 44.8% | ||||
| HealthEquity shareholders | ||||||||||
